NantHealth Continues Global Expansion of GPS Cancer™ by Bringing Advanced Genomic Profiling to Patients in Mexico
08 August 2017 - 12:29AM
Business Wire
Sistemas Medicos Nacionales becomes first
international payer to cover GPS Cancer™ for patients, bringing a
new standard of cancer care to Mexico
NantHealth, Inc. (Nasdaq: NH), a leading next-generation,
evidence-based, personalized healthcare company, today
announced that GPS Cancer, a molecular test that helps guide cancer
treatment strategies including choice of standard chemotherapy for
oncologists, is now covered by Sistemas Medicos Nacionales, S.A. de
C.V. (SIMNSA), a comprehensive healthcare service plan that
provides quality care for patients in the cities of Tijuana, Tecate
and Mexicali. With the availability and coverage of GPS Cancer,
oncologists can now provide patients in northern Mexico with a more
precise, personalized approach to their cancer care. The
partnership marks the next step in the international expansion of
GPS Cancer, which was recently also made available in Italy, Israel
and the Middle East.
“In 2012, the cancer incidence rate in Mexico stood at 148,000i
and continue to rise,” said Patrick Soon-Shiong, MD, CEO of
NantHealth. “We’re excited about the availability and coverage of
GPS Cancer in Mexico and believe this news is supporting our
ongoing commitment to the fight against cancer. We will continue
with our global efforts to strive to usher in the era of
quantitative proteomics and personalized treatment plans.”
The most common cancer types in Mexico are breast, colon,
prostate and cervix. Under the terms of the agreement, SIMNSA will
cover GPS Cancer for approximately 47,000 members in its healthcare
plan. As one of the most prominent Health Maintenance Organization
(HMO) programs in northern Mexico, SIMNSA was the first Mexican HMO
to be licensed as a healthcare service plan by the state of
California. It is also one of the largest private healthcare
delivery systems in Baja, California, with more than 200
participating physicians covering all specialties of medicine.
“Our partnership with NantHealth is an important step in
advancing SIMNSA’s progress in establishing more advanced cancer
care for patients in Mexico,” said Christina Suggett, Chief
Operating Officer, SIMNSA Health Plan. “SIMNSA is in the ideal
position to bring the GPS Cancer test to Mexico and we’re proud to
offer a tailored approach to their cancer treatment plans.”
GPS Cancer, a unique molecular profile performed in the
CLIA-certified, CAP-accredited laboratories of NantOmics,
integrates whole genome (DNA) sequencing, whole transcriptome (RNA)
sequencing, and quantitative proteomics to provide oncologists with
a comprehensive molecular profile of a patient’s cancer to inform
personalized treatment strategies. GPS Cancer provides critical
insights based on the unique biology of a patient’s tumor—from the
DNA to the RNA to the protein. The richness of this information
helps doctors to build potentially more effective treatment plans
based on current drugs and active clinical trials, while enabling
cancer researchers to design new clinical trials that harness the
potential of the immune system.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding the
capabilities and anticipated utility of our GPS Cancer, including
predicting patient response and resistance to therapeutics,
enabling diagnoses by physicians and accelerating efforts to bring
novel combinations of therapeutic agents to cancer patients.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results. Factors that may cause future
results to differ materially from management’s current expectations
include, among other things, that GPS Cancer may not perform as
anticipated, that sufficient physicians may not adopt GPS Cancer to
assist their diagnoses or that healthcare payers may not provide
reimbursement for GPS Cancer as expected. Our business is subject
to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities;
our planned sales, marketing, and research and development
activities; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
our business and operating results can be found in our existing and
future filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. We
disclaim any obligation to update these forward-looking statements
except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissues and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system, which includes its unique software, middleware and hardware
systems infrastructure that collects, indexes, analyzes and
interprets billions of molecular, clinical, operational and
financial data points derived from novel and traditional sources,
continuously improves decision-making and further optimizes our
clinical pathways and decision algorithms over time. For more
information please visit www.nanthealth.com and follow
Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through
NantHealth. GPS Cancer integrates whole genome (DNA) sequencing,
whole transcriptome (RNA) sequencing, and quantitative proteomics
through mass spectrometry, providing oncologists with a
comprehensive molecular profile of a patient's cancer and an
assessment of protein pathway function to inform personalized
treatment strategies. GPS Cancer scanning is conducted in
CLIA-certified and CAP-accredited laboratories, and is a key
enabler for Cancer Breakthroughs 2020, the world's most
comprehensive cancer collaborative initiative seeking to accelerate
the potential of combination immunotherapy as the next generation
standard of care in cancer patients. For more information,
visit www.gpscancer.com.
i See http://www.cancerindex.org/Mexico.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170807005591/en/
NantWorksJen Hodsonjohodson@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024